With vaccine development prioritized during the COVID-19 pandemic, innovations have to accelerated development processes.

Overcoming Vaccine Development Challenges

The inhaled route of administration for biologics is experiencing renewed interest.

Taking a Breath: Advances in Inhaled Biologics

Topic

Articles

GoSilico’s software for digital twins of downstream biopharmaceutical processes will be integrated into Cytiva.

Cytiva Acquires German Software Maker GoSilico 

Currently, PNI offers a Genetic Medicine Toolkit, including its GenVoy LNP delivery platform and NanoAssemblr microfluidic-based nanoparticle manufacturing platform, for the development of genetic medicines.

PNI to be Acquired by Danaher Corporation’s Life Sciences Platform

Feliza Mirasol is the science editor for 

The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

Next-Gen Therapies Drive Development Technologies

Yan He is the senior scientist at BioSpherix, Ltd., 25 union St. Parish, NY

Shannon Darou is a technician at BioSpherix, Ltd., 25 union St. Parish, NY

Stassa P.D. Henn is an intern at BioSpherix, Ltd., 25 union St. Parish, NY

Rose Walter is an intern at BioSpherix, Ltd., 25 union St. Parish, NY

Randy Yerden is the chief executive officer at BioSpherix, Ltd., 25 union St. Parish, NY

Alicia D. Henn is the chief scientific officer, all at BioSpherix, Ltd., 25 union St. Parish, NY

Controlling certain atmospheric conditions in a closed NGI processing chamber can reduce bioburden without disinfectants. 

Temperature and Relative Humidity Control to Reduce Bioburden in a Closed Cell Processing and Production System without Disinfectants

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

Meeting the Demand for Lipid Excipients 

Editor of Pharmaceutical Technology Europe

Outsourcing method development offers multiple benefits to companies, including access to experience and expertise, streamlined costs, and development time efficiencies.

Developing a Method for Success through Partnerships

Developing and manufacturing a therapy in a regulated environment demands careful adherence to quality practices. 

Regulatory Requirements for Biologic Drug Development

Under the terms of the agreement, Thermo Fisher will construct and operate a 44,000-ft2 cell therapy development, manufacturing, and collaboration center on UCSF's Mission Bay campus.

Thermo Fisher and UCSF Enter into Alliance to Accelerate Cell Therapy Development

Bristol Myers Squibb has entered into a definitive agreement with Agenus for a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.

Bristol Myers Squibb Enters into Agreement with Agenus for Up to $1.56 Billion 

Charles River plans to enhance its gene therapy capabilities through the acquisition of Vigene Biosciences. 